Cargando…
15 years journey of idiopathic pulmonary arterial hypertension with BMPR2 mutation
Pulmonary arterial hypertension (PAH) is known as one of diseases with the worst prognosis. Recently, targeted PAH drugs have been developed and approved for use; therefore, the treatment strategy and goals have changed, and the prognosis has improved over two decades. We reviewed the case of a fema...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771102/ https://www.ncbi.nlm.nih.gov/pubmed/31583114 http://dx.doi.org/10.1186/s40885-019-0127-7 |